SG11202000418XA - Heterocyclic compounds as adenosine antagonists - Google Patents
Heterocyclic compounds as adenosine antagonistsInfo
- Publication number
- SG11202000418XA SG11202000418XA SG11202000418XA SG11202000418XA SG11202000418XA SG 11202000418X A SG11202000418X A SG 11202000418XA SG 11202000418X A SG11202000418X A SG 11202000418XA SG 11202000418X A SG11202000418X A SG 11202000418XA SG 11202000418X A SG11202000418X A SG 11202000418XA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- adenosine antagonists
- adenosine
- antagonists
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762534176P | 2017-07-18 | 2017-07-18 | |
PCT/US2018/042777 WO2019018584A1 (en) | 2017-07-18 | 2018-07-18 | Heterocyclic compounds as adenosine antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202000418XA true SG11202000418XA (en) | 2020-02-27 |
Family
ID=65014543
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202000418XA SG11202000418XA (en) | 2017-07-18 | 2018-07-18 | Heterocyclic compounds as adenosine antagonists |
Country Status (11)
Country | Link |
---|---|
US (2) | US11028058B2 (en) |
EP (1) | EP3654978A4 (en) |
JP (1) | JP2020527588A (en) |
KR (1) | KR20200041315A (en) |
CN (1) | CN111163780A (en) |
AU (1) | AU2018302179A1 (en) |
CA (1) | CA3070273A1 (en) |
IL (1) | IL272056A (en) |
MX (1) | MX2020000690A (en) |
SG (1) | SG11202000418XA (en) |
WO (1) | WO2019018584A1 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
WO2019232223A1 (en) * | 2018-05-30 | 2019-12-05 | University Of Notre Dame Du Lac | Hsp90 beta selective inhibitors |
CN110655509B (en) * | 2018-06-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 2-aminopyrimidine derivatives, preparation method and medical application thereof |
CN111094254B (en) * | 2018-07-12 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | Heteroaryl derivative, preparation method and application thereof in medicine |
WO2020035052A1 (en) * | 2018-08-17 | 2020-02-20 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Pyrazine compounds and uses thereof |
CN113166119B (en) * | 2018-12-28 | 2024-01-05 | 四川科伦博泰生物医药股份有限公司 | Substituted aryl compound and preparation method and application thereof |
CN111377906B (en) * | 2018-12-28 | 2022-09-02 | 四川科伦博泰生物医药股份有限公司 | Substituted pyrazine compounds, their preparation and use |
AU2020207952A1 (en) * | 2019-01-18 | 2021-08-26 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
MX2021008650A (en) * | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Heterocyclic compounds as adenosine antagonists. |
BR112022001341A2 (en) * | 2019-08-21 | 2022-03-22 | Kalvista Pharmaceuticals Ltd | enzyme inhibitors |
US11926632B2 (en) | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
KR102646627B1 (en) * | 2021-03-24 | 2024-03-13 | 주식회사 스탠다임 | Dual antagonist of adenosine A2A receptor and adenosine A2B receptor, and use thereof |
WO2022268520A1 (en) * | 2021-06-21 | 2022-12-29 | Bayer Aktiengesellschaft | Use of substituted pyrrolidinones or their salts for increasing stress tolerance of plants |
WO2023064585A1 (en) * | 2021-10-14 | 2023-04-20 | Vanderbilt University | 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders |
CN113968824B (en) * | 2021-11-29 | 2024-01-19 | 郑州大学 | 2,3, 5-trisubstituted pyrazine compound and preparation method and application thereof |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
DK1603570T5 (en) | 2003-02-26 | 2013-12-09 | Sugen Inc | AMINOHETEROARYL COMPOUNDS AS PROTEINKINASE INHIBITORS |
AU2004224392A1 (en) | 2003-03-24 | 2004-10-07 | Merck & Co., Inc. | Biaryl substituted 6-membered heterocyles as sodium channel blockers |
BRPI0415863A (en) | 2003-10-27 | 2007-01-09 | Astellas Pharma Inc | pyrazine derivatives and their pharmaceutical uses |
ATE452890T1 (en) | 2003-11-04 | 2010-01-15 | Merck & Co Inc | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES |
ES2270715B1 (en) * | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF PIRAZINA. |
GB0800741D0 (en) * | 2008-01-16 | 2008-02-20 | Univ Greenwich | Cyclic triazo and diazo sodium channel blockers |
CN101970418B (en) | 2008-02-01 | 2013-07-03 | 阿基宁医药品公司 | Pyrazine derivative and its uses as protein kinase inhibitor |
CN102333779B (en) | 2008-03-31 | 2015-12-09 | 吉宁特有限公司 | Chromene and benzo oxa-* PI3K inhibitor compound and using method |
WO2010088177A1 (en) | 2009-02-02 | 2010-08-05 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
HUE028640T2 (en) | 2010-02-05 | 2016-12-28 | Heptares Therapeutics Ltd | 1,2,4-triazine-4-amine derivatives |
EP2593452B1 (en) | 2010-07-14 | 2017-01-18 | Novartis AG | Ip receptor agonist heterocyclic compounds |
EP2718978B1 (en) * | 2011-06-09 | 2018-05-16 | Novaled GmbH | Organic electronic device |
CN104053659B (en) | 2012-01-13 | 2016-11-09 | 诺华股份有限公司 | For treating the pyroles condensed as IP receptor stimulating agent of pulmonary hypertension (PAH) and associated conditions |
US9266891B2 (en) | 2012-11-16 | 2016-02-23 | Boehringer Ingelheim International Gmbh | Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors |
US9675697B2 (en) | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
EP2968322B1 (en) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
PT3010503T (en) | 2013-06-21 | 2020-06-16 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
CN104341386A (en) * | 2013-07-23 | 2015-02-11 | 中国科学院上海药物研究所 | Aryl heterocycle micromolecule compounds, derivatives thereof, and preparing methods and uses of the compounds and the derivatives |
WO2015017335A1 (en) | 2013-07-30 | 2015-02-05 | Boehringer Ingelheim International Gmbh | Azaindole compounds as modulators of rorc |
US9422281B2 (en) | 2013-11-18 | 2016-08-23 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
LT3071203T (en) | 2013-11-18 | 2021-05-25 | Forma Therapeutics, Inc. | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
JP2017511801A (en) | 2014-02-28 | 2017-04-27 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | 9H-pyrimido [4,5-b] indoles and related analogs as BET bromodomain inhibitors |
CA2946731C (en) | 2014-04-23 | 2022-06-07 | Incyte Corporation | 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins |
CN107106558A (en) | 2014-11-18 | 2017-08-29 | 默沙东公司 | With A2AThe Aminopyrazine compound of antagonist properties |
US10292968B2 (en) | 2014-12-11 | 2019-05-21 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
US10307407B2 (en) | 2015-02-27 | 2019-06-04 | The Regents Of The University Of Michigan | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors |
US10336697B2 (en) | 2015-06-16 | 2019-07-02 | Orion Corporation | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors |
KR102114562B1 (en) | 2015-08-11 | 2020-05-26 | 노파르티스 아게 | 5-bromo-2,6-di- (1H-pyrazol-1-yl) pyrimidin-4-amine for use in the treatment of cancer |
WO2017053243A1 (en) | 2015-09-21 | 2017-03-30 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
WO2017050714A1 (en) | 2015-09-22 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
AU2016379425B2 (en) | 2015-12-24 | 2021-11-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
WO2018005533A1 (en) | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Antiproliferative pyrimidine-based compounds |
JP2019520379A (en) | 2016-07-01 | 2019-07-18 | ジー1 セラピューティクス, インコーポレイテッド | Pyrimidine antiproliferative agents |
AU2017290362B2 (en) | 2016-07-01 | 2021-08-05 | G1 Therapeutics, Inc. | Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines |
GB201612092D0 (en) | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
WO2018081863A1 (en) | 2016-11-04 | 2018-05-11 | University Of Wollongong | 6-SUBSTITUTED DERIVATIVES OF HEXAMETHYLENE AMILORIDE AS INHIBITORS OF uPA AND USES THEREOF |
EP3570844B1 (en) | 2017-01-20 | 2023-09-06 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
TWI801372B (en) | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | Thiocarbamate derivatives as a2a inhibitors and methods for use in the treatment of cancers |
EP4112623A1 (en) | 2017-03-30 | 2023-01-04 | iTeos Belgium SA | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
CN107221611B (en) | 2017-06-15 | 2019-02-05 | 江西冠能光电材料有限公司 | A kind of stable easy processing organic semiconducting materials and its organic luminescent device application |
AU2018294557A1 (en) | 2017-06-30 | 2020-01-02 | Ryvu Therapeutics S.A. | Imidazo(1,2-a)pyrazine modulators of the adenosine A2A receptor |
CA3070073A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
US20210008206A1 (en) | 2017-11-06 | 2021-01-14 | Corvus Pharmaceuticals, Inc. | Adenosine pathway inhibitors for cancer treatment |
CN109810111B (en) | 2017-11-20 | 2023-10-27 | 上海医药集团股份有限公司 | Pyrazolopyrimidine compound, and preparation method and application thereof |
WO2019118313A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
EP3719017A4 (en) | 2017-12-20 | 2020-12-02 | Betta Pharmaceuticals Co., Ltd. | Compound functioning as bromodomain protein inhibitor, and composition |
CN111315747B (en) | 2018-01-05 | 2023-05-02 | 四川科伦博泰生物医药股份有限公司 | Dihydropyrazolopyrimidine compound and preparation method and application thereof |
EP3741758A1 (en) | 2018-01-16 | 2020-11-25 | Shanghai Institute of Materia Medica, Chinese Academy of Sciences | Bromodomain inhibitor compound and use thereof |
SG11202006748RA (en) | 2018-01-29 | 2020-08-28 | Beta Pharma Inc | 2h-indazole derivatives as cdk4 and cdk6 inhibitors and therapeutic uses thereof |
US20210032253A1 (en) | 2018-02-06 | 2021-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo[1,5-a][1,3,5]triazine-2-amine derivative, preparation method therefor and medical use thereof |
WO2019160829A1 (en) | 2018-02-13 | 2019-08-22 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists |
WO2019158070A1 (en) | 2018-02-15 | 2019-08-22 | 杭州阿诺生物医药科技有限公司 | A2a and/or a2b receptor antagonist |
WO2019165204A1 (en) | 2018-02-23 | 2019-08-29 | Newave Pharmaceutical Inc. | 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidine-3-one compounds as inhibitors of wee-1 kinase |
US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
EP3758706A4 (en) | 2018-02-28 | 2021-11-24 | The Regents Of The University Of Colorado | Wee1 kinase inhibitors and methods of treating cancer using the same |
CN117720541A (en) | 2018-03-09 | 2024-03-19 | 里科瑞尔姆Ip控股有限责任公司 | Substituted 1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-ones |
US11220510B2 (en) | 2018-04-09 | 2022-01-11 | Incyte Corporation | Pyrrole tricyclic compounds as A2A / A2B inhibitors |
WO2020035052A1 (en) | 2018-08-17 | 2020-02-20 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Pyrazine compounds and uses thereof |
AR116315A1 (en) | 2018-09-12 | 2021-04-21 | Dizal Jiangsu Pharmaceutical Co Ltd | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES OF THEM |
MX2021008650A (en) | 2019-01-18 | 2021-11-03 | Nuvation Bio Inc | Heterocyclic compounds as adenosine antagonists. |
US11254670B2 (en) | 2019-01-18 | 2022-02-22 | Nuvation Bio Inc. | 1,8-naphthyridinone compounds and uses thereof |
-
2018
- 2018-07-18 SG SG11202000418XA patent/SG11202000418XA/en unknown
- 2018-07-18 WO PCT/US2018/042777 patent/WO2019018584A1/en unknown
- 2018-07-18 MX MX2020000690A patent/MX2020000690A/en unknown
- 2018-07-18 JP JP2020502984A patent/JP2020527588A/en active Pending
- 2018-07-18 KR KR1020207004248A patent/KR20200041315A/en not_active Application Discontinuation
- 2018-07-18 AU AU2018302179A patent/AU2018302179A1/en not_active Abandoned
- 2018-07-18 EP EP18834623.3A patent/EP3654978A4/en not_active Withdrawn
- 2018-07-18 US US16/039,307 patent/US11028058B2/en active Active
- 2018-07-18 CN CN201880059365.8A patent/CN111163780A/en active Pending
- 2018-07-18 CA CA3070273A patent/CA3070273A1/en active Pending
-
2020
- 2020-01-15 IL IL272056A patent/IL272056A/en unknown
-
2021
- 2021-02-12 US US17/175,159 patent/US20210292285A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3654978A4 (en) | 2021-03-31 |
US20190023666A1 (en) | 2019-01-24 |
US20210292285A1 (en) | 2021-09-23 |
IL272056A (en) | 2020-03-31 |
CA3070273A1 (en) | 2019-01-24 |
AU2018302179A1 (en) | 2020-02-13 |
EP3654978A1 (en) | 2020-05-27 |
US11028058B2 (en) | 2021-06-08 |
JP2020527588A (en) | 2020-09-10 |
CN111163780A (en) | 2020-05-15 |
MX2020000690A (en) | 2020-07-29 |
KR20200041315A (en) | 2020-04-21 |
WO2019018584A1 (en) | 2019-01-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
IL289793A (en) | Heterocyclic compounds as ret kinase inhibitors | |
ZA201807249B (en) | Heterocyclic compound | |
SI3442535T1 (en) | Heterocyclic compounds as ret kinase inhibitors | |
RS63359B1 (en) | Heterocyclic compounds as pi3k-gamma inhibitors | |
IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
IL254424A0 (en) | Substituted tricyclic heterocyclic compounds | |
SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
IL284767A (en) | Heterocyclic compounds as adenosine antagonists | |
IL284762A (en) | Heterocyclic compounds as adenosine antagonists | |
EP3660003C0 (en) | Heterocyclic compound | |
IL271799A (en) | Novel substituted xanthine derivatives | |
EP3693360C0 (en) | Heterocyclic compounds | |
EP3693368C0 (en) | Heterocyclic compound | |
SG11202001337XA (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
IL254890A0 (en) | Heterocyclic compound | |
IL262448B (en) | Substituted bicyclic heterocyclic compounds | |
PT3643718T (en) | Heterocyclic compound | |
ZA201907792B (en) | Heterocyclic compound | |
ZA201907793B (en) | Heterocyclic compound | |
IL266099A (en) | Heterocyclic compound |